Association Between Disease-Modifying Therapies and Adverse Clinical Outcomes in Multiple Sclerosis Patients With Covid-19 Infection Publisher Pubmed



Maghbooli Z¹ ; Hosseinpour H³ ; Fattahi MR¹ ; Varzandi T¹ ; Hamtaeigashi S¹ ; Mohammadnabi S¹ ; Aghababaei Y² ; Sahraian MA¹
Source: Multiple Sclerosis and Related Disorders Published:2022

Abstract

Background: This study aimed to consider the main risk factors related to adverse clinical outcomes in MS patients with COVID-19. Methods: Using the electronic health records systems, this is a cross-sectional study of two years of hospital admissions in terms of COVID-19 in Iran from March 2019 to August 2021. The severities of COVID-19 outcomes were admitted to ICU, hospitalization days, and in-hospital mortality. Results: A total of 1634 hospitalized MS patients with a definite diagnosis of COVID-19 based on PCR were recorded in the electronic health systems. MS patients had a 7% increased risk for longer hospitalization, a 3% increased risk for the need to the ICU, and no increased risk of mortality compared with the general population. MS patients who were taking immunosuppressive (IS)-disease modifying therapies (DMT) had longer hospitalization (adjusted OR=2.06, 95%CI: 1.48, 2.86) and higher mortality risk (adjusted OR=2.05, 95%CI: 1.52, 6.29) compared to patients were under the immunomodulatory (IM)-DMT. There was not any significant association between the types of DMT and ICU (12.2% vs. 12.7%). Besides, MS patients who were vaccinated against COVID-19 before admission had shorter hospitalization (adjusted OR=0.40, 95% CI: 0.18, 0.92). Conclusions: The current data suggest that MS healthcare providers should consider specific risks of severe COVID-19 infection before starting IS-DMT. © 2022